From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Decoglurant structure.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development terminated
CAS Number
  • 911115-16-7
PubChem CID
  • 71533696
  • 32695160
  • D10875
Chemical and physical data
Formula C21H11F6N5
Molar mass 447.336 g/mol g·mol−1
3D model (JSmol)
  • Interactive image

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also


  1. ^ a b "Roche – Pipeline". 2014. Retrieved 2014-08-01.
  2. ^ a b "Roche Group Development Pipeline" (PDF). 2014. Archived from the original (PDF) on 2014-08-08. Retrieved 2014-08-01. Cite uses deprecated parameter |deadurl= (help)
  3. ^ "Roche – Pipeline" (PDF). 2015. Archived from the original (PDF) on 2015-05-01. Retrieved 2015-05-14. Cite uses deprecated parameter |dead-url= (help)
  4. ^ Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal.

External links

  • Decoglurant – AdisInsight – Springer
Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "Decoglurant"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA